234 related articles for article (PubMed ID: 35764927)
1. The role of epigenetic modifications in drug resistance and treatment of breast cancer.
Karami Fath M; Azargoonjahromi A; Kiani A; Jalalifar F; Osati P; Akbari Oryani M; Shakeri F; Nasirzadeh F; Khalesi B; Nabi-Afjadi M; Zalpoor H; Mard-Soltani M; Payandeh Z
Cell Mol Biol Lett; 2022 Jun; 27(1):52. PubMed ID: 35764927
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.
Trnkova L; Buocikova V; Mego M; Cumova A; Burikova M; Bohac M; Miklikova S; Cihova M; Smolkova B
Biomed Pharmacother; 2024 May; 174():116559. PubMed ID: 38603889
[TBL] [Abstract][Full Text] [Related]
3. Beyond genetics: Exploring the role of epigenetic alterations in breast cancer.
Prabhu KS; Sadida HQ; Kuttikrishnan S; Junejo K; Bhat AA; Uddin S
Pathol Res Pract; 2024 Feb; 254():155174. PubMed ID: 38306863
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance in ovarian cancer: from mechanism to clinical trial.
Wang L; Wang X; Zhu X; Zhong L; Jiang Q; Wang Y; Tang Q; Li Q; Zhang C; Wang H; Zou D
Mol Cancer; 2024 Mar; 23(1):66. PubMed ID: 38539161
[TBL] [Abstract][Full Text] [Related]
5. A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance.
Das C; Bhattacharya A; Adhikari S; Mondal A; Mondal P; Adhikary S; Roy S; Ramos K; Yadav KK; Tainer JA; Pandita TK
Oncogene; 2024 Jun; 43(23):1727-1741. PubMed ID: 38719949
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance.
Sadida HQ; Abdulla A; Marzooqi SA; Hashem S; Macha MA; Akil ASA; Bhat AA
Transl Oncol; 2024 Jan; 39():101821. PubMed ID: 37931371
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?
Fucito A; Lucchetti C; Giordano A; Romano G
Int J Biochem Cell Biol; 2008; 40(4):565-75. PubMed ID: 18061512
[TBL] [Abstract][Full Text] [Related]
8. Editorial: Heterogeneity in breast cancer: clinical and therapeutic implications.
Carlino F; Solinas C; Orditura M; Bisceglia MD; Pellegrino B; Diana A
Front Oncol; 2024; 14():1321654. PubMed ID: 38469228
[No Abstract] [Full Text] [Related]
9. Long non-coding RNA mediated drug resistance in breast cancer.
Singh D; Assaraf YG; Gacche RN
Drug Resist Updat; 2022 Jul; 63():100851. PubMed ID: 35810716
[TBL] [Abstract][Full Text] [Related]
10. The Mechanism of DNA Methylation and miRNA in Breast Cancer.
Ma L; Li C; Yin H; Huang J; Yu S; Zhao J; Tang Y; Yu M; Lin J; Ding L; Cui Q
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298314
[TBL] [Abstract][Full Text] [Related]
11. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
Szczepanek J; Skorupa M; Jarkiewicz-Tretyn J; Cybulski C; Tretyn A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108398
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells.
Lee PWT; Koseki LR; Haitani T; Harada H; Kobayashi M
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730681
[TBL] [Abstract][Full Text] [Related]
13. Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.
Abdul Manap AS; Wisham AA; Wong FW; Ahmad Najmi HR; Ng ZF; Diba RS
Front Cell Dev Biol; 2024; 12():1390704. PubMed ID: 38726321
[TBL] [Abstract][Full Text] [Related]
14. Elevated level of neuroserpin is an indication for the resistance to gambogic acid-induced apoptosis and oxidative stress in triple-negative breast cancer cells.
Kucuksayan E; Kucuksayan H; Sozen ME; Sircan-Kucuksayan A
Asian Biomed (Res Rev News); 2024 Apr; 18(2):69-80. PubMed ID: 38708330
[TBL] [Abstract][Full Text] [Related]
15. IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.
Lv L; Wei Q; Zhang J; Dong Y; Shan Z; Chang N; Zhao Y; Bian P; Yi Q
Cell Mol Biol Lett; 2024 Mar; 29(1):39. PubMed ID: 38504159
[TBL] [Abstract][Full Text] [Related]
16. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.
Tufail M; Hu JJ; Liang J; He CY; Wan WD; Huang YQ; Jiang CH; Wu H; Li N
J Transl Med; 2024 Jan; 22(1):15. PubMed ID: 38172946
[TBL] [Abstract][Full Text] [Related]
17. Targeting ferroptosis in melanoma: cancer therapeutics.
Khorsandi K; Esfahani H; Ghamsari SK; Lakhshehei P
Cell Commun Signal; 2023 Nov; 21(1):337. PubMed ID: 37996827
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC.
Wu X; Lu W; Zhang W; Zhang D; Mei H; Zhang M; Cui Y; Zhuo Z
Aging (Albany NY); 2023 Nov; 15(21):12674-12697. PubMed ID: 37963845
[TBL] [Abstract][Full Text] [Related]
19. Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.
da Silva FC; Brandão DC; Ferreira EA; Siqueira RP; Ferreira HSV; Da Silva Filho AA; Araújo TG
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895937
[TBL] [Abstract][Full Text] [Related]
20. Visualization of breast cancer-related protein synthesis from the perspective of bibliometric analysis.
Xu J; Yu C; Zeng X; Tang W; Xu S; Tang L; Huang Y; Sun Z; Yu T
Eur J Med Res; 2023 Oct; 28(1):461. PubMed ID: 37885035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
